Arrowhead Pharmaceuticals Overview

  • Year Founded
  • 1989

Year Founded

  • Status
  • Public

  • Employees
  • 525

Employees

  • Stock Symbol
  • ARWR

Stock Symbol

  • Investments
  • 11

  • Share Price
  • $25.10
  • (As of Monday Closing)

Arrowhead Pharmaceuticals General Information

Description

Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.

Contact Information

Formerly Known As
InterActive Group, Arrowhead Research, Arrowhead Research Corp, Interactive Group Inc
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Corporate Office
  • 177 East Colorado Boulevard
  • Suite 700
  • Pasadena, CA 91105
  • United States
+1 (626) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Arrowhead Pharmaceuticals Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$25.10 $25.84 $20.67 - $39.83 $3.21B 124M 965K -$4.22

Arrowhead Pharmaceuticals Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2023 30-Sep-2023 FY 2022 30-Sep-2022 FY 2021 30-Sep-2021
EV 3,455,058 2,528,459 3,183,176 6,016,737
Revenue 35,473 240,735 243,231 138,287
EBITDA (456,213) (190,971) (167,321) (138,699)
Net Income (470,789) (205,275) (176,063) (140,848)
Total Assets 955,150 765,552 691,939 710,148
Total Debt 118,917 115,171 81,576 25,545
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Arrowhead Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Arrowhead Pharmaceuticals‘s full profile, request access.

Request a free trial

Arrowhead Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to tr
Biotechnology
Pasadena, CA
525 As of 2023
00.000
00000000 00.000

000000

t dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamc
0000 000000000
Cambridge, MA
0000 As of 0000
00.000
0000 00.000

000000

s nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderi
0000000000000
Allschwil, Switzerland
000 As of 0000
00.000
00000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Arrowhead Pharmaceuticals Competitors (90)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Alnylam Pharmaceuticals Formerly VC-backed Cambridge, MA 0000 00.000 0000 00.000
Idorsia Pharmaceuticals Corporate Backed or Acquired Allschwil, Switzerland 000 00.000 00000000 00.000
Alpine Immune Sciences Pending Transaction (M&A) Seattle, WA 000 00000 000000&0 00000
Regulus Therapeutics Formerly VC-backed San Diego, CA 00 00000 000000000 00000
Dicerna Pharmaceuticals Formerly VC-backed Lexington, MA 000 00000 000000&0 00000
You’re viewing 5 of 90 competitors. Get the full list »

Arrowhead Pharmaceuticals Patents

Arrowhead Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240167035-A1 Rnai agents for inhibiting expression of complement component c3 (c3), pharmaceutical compositions thereof, and methods of use Pending 27-Oct-2022 0000000000
US-11912997-B2 Rnai agents for inhibiting expression of superoxide dismutase 1 (sod1), compositions thereof, and methods of use Active 15-Jun-2022 00000000000 00
US-20240026363-A1 Rnai agents for inhibiting expression of superoxide dismutase 1 (sod1), compositions thereof, and methods of use Active 15-Jun-2022 00000000000 0
US-20230265437-A1 Rnai agents for inhibiting expression of matrix metalloproteinase 7 (mmp7), compositions thereof, and methods of use Pending 22-Oct-2021 00000000000
AU-2022368927-A1 Rnai agents for inhibiting expression of matrix metalloproteinase 7(mmp7), compositions thereof, and methods of use Pending 22-Oct-2021 C12N15/1137
To view Arrowhead Pharmaceuticals’s complete patent history, request access »

Arrowhead Pharmaceuticals Executive Team (17)

Name Title Board Seat Contact Info
Christopher Anzalone Ph.D Chief Executive Officer, President & Board Member
Kenneth Myszkowski Chief Financial Officer
Patrick O'Brien JD Chief Operating Officer, Operations & General Counsel, Legal
Bruce Given MD Executive
James Hamilton Executive
You’re viewing 5 of 17 executive team members. Get the full list »

Arrowhead Pharmaceuticals Board Members (12)

Name Representing Role Since
000000 00000000 00 Self Board Member 000 0000
00000000000 000000 Arrowhead Pharmaceuticals Chief Executive Officer, President & Board Member 000 0000
00000000 00000 00 Self Chairman & Board Member 000 0000
00000000 00 000000 Self Board Member 000 0000
00000 0000000 00.0 Self Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

Arrowhead Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Arrowhead Pharmaceuticals Investments & Acquisitions (11)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Visirna Therapeutics 29-Apr-2022 00000 0000 0000 Drug Discovery
Visirna(Arrowhead/Vivo) 25-Apr-2022 00000 0000 0000 Drug Discovery
Novartis (RNAI Research and Development Portfolio) 05-Mar-2015 0000000000 0000 Biotechnology 000000000
Alvos Therapeutics 11-Apr-2012 0000000000 000 Drug Discovery
Roche Holding (RNA Therapeutics Business) 24-Oct-2011 Merger/Acquisition 00.00 Drug Delivery 000000000
You’re viewing 5 of 11 investments and acquisitions. Get the full list »

Arrowhead Pharmaceuticals ESG

Risk Overview

Risk Rating

Updated March, 01, 2024

25.8 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 16,191

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 921

Rank

00.0

Percentile

Biotechnology

Subindustry

00 of 405

Rank

00.00

Percentile

To view Arrowhead Pharmaceuticals’s complete esg history, request access »

Arrowhead Pharmaceuticals Exits (5)

Company Name Exit Date Exit Type Exit Size Status Buyers
Unidym 01-Aug-2008 000000000000000000 00000 Completed
  • 000000000 00000000
Unidym 17-Jun-2008 00000 00000 00 000 Completed
  • 2 buyers
Calando Pharmaceuticals 16-Oct-2006 00000 00000 00 000.00 Completed
  • 2 buyers
Calando Pharmaceuticals 04-Jun-2004 000000000000000000 Completed
  • 000000000 00000000
Unidym Later Stage VC 000 Completed
To view Arrowhead Pharmaceuticals’s complete exits history, request access »

Arrowhead Pharmaceuticals FAQs

  • When was Arrowhead Pharmaceuticals founded?

    Arrowhead Pharmaceuticals was founded in 1989.

  • Who is the CEO of Arrowhead Pharmaceuticals?

    Christopher Anzalone Ph.D is the CEO of Arrowhead Pharmaceuticals.

  • Where is Arrowhead Pharmaceuticals headquartered?

    Arrowhead Pharmaceuticals is headquartered in Pasadena, CA.

  • What is the size of Arrowhead Pharmaceuticals?

    Arrowhead Pharmaceuticals has 525 total employees.

  • What industry is Arrowhead Pharmaceuticals in?

    Arrowhead Pharmaceuticals’s primary industry is Biotechnology.

  • Is Arrowhead Pharmaceuticals a private or public company?

    Arrowhead Pharmaceuticals is a Public company.

  • What is Arrowhead Pharmaceuticals’s stock symbol?

    The ticker symbol for Arrowhead Pharmaceuticals is ARWR.

  • What is the current stock price of Arrowhead Pharmaceuticals?

    As of 17-Jun-2024 the stock price of Arrowhead Pharmaceuticals is $25.10.

  • What is the current market cap of Arrowhead Pharmaceuticals?

    The current market capitalization of Arrowhead Pharmaceuticals is $3.21B.

  • What is Arrowhead Pharmaceuticals’s current revenue?

    The trailing twelve month revenue for Arrowhead Pharmaceuticals is $35.5M.

  • Who are Arrowhead Pharmaceuticals’s competitors?

    Alnylam Pharmaceuticals, Idorsia Pharmaceuticals, Alpine Immune Sciences, Regulus Therapeutics, and Dicerna Pharmaceuticals are some of the 90 competitors of Arrowhead Pharmaceuticals.

  • What is Arrowhead Pharmaceuticals’s annual earnings per share (EPS)?

    Arrowhead Pharmaceuticals’s EPS for 12 months was -$4.22.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »